Stock Worth Mentioning: What’s Ahead for Versartis Inc After Today’s Huge Decline?

Stock Worth Mentioning: What's Ahead for Versartis Inc After Today's Huge Decline?

The stock of Versartis Inc (NASDAQ:VSAR) is a huge mover today! About 162,977 shares traded hands. Versartis Inc (NASDAQ:VSAR) has risen 77.03% since March 9, 2016 and is uptrending. It has outperformed by 69.61% the S&P500.
The move comes after 7 months negative chart setup for the $394.02 million company. It was reported on Oct, 12 by We have $10.49 PT which if reached, will make NASDAQ:VSAR worth $39.40M less.

Analysts await Versartis Inc (NASDAQ:VSAR) to report earnings on November, 3. They expect $-0.84 EPS, down 21.74% or $0.15 from last year’s $-0.69 per share. After $-0.75 actual EPS reported by Versartis Inc for the previous quarter, Wall Street now forecasts 12.00% negative EPS growth.

Versartis Inc (NASDAQ:VSAR) Ratings Coverage

Out of 6 analysts covering Versartis Inc (NASDAQ:VSAR), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Versartis Inc has been the topic of 8 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The stock of Versartis Inc (NASDAQ:VSAR) has “Outperform” rating given on Thursday, April 7 by Northland Capital. The firm has “Buy” rating by Canaccord Genuity given on Monday, September 21. Citigroup maintained the stock with “Buy” rating in Thursday, August 11 report. Piper Jaffray initiated the stock with “Overweight” rating in Tuesday, October 4 report. The firm has “Neutral” rating given on Thursday, August 20 by Credit Suisse. Credit Suisse downgraded Versartis Inc (NASDAQ:VSAR) on Thursday, December 17 to “Underperform” rating. As per Thursday, August 13, the company rating was initiated by Morgan Stanley.

According to Zacks Investment Research, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.”

Insitutional Activity: The institutional sentiment increased to 3 in 2016 Q2. Its up 1.93, from 1.07 in 2016Q1. The ratio is positive, as 5 funds sold all Versartis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 34 increased positions. They now own 20.36 million shares or 0.09% more from 20.34 million shares in 2016Q1.
The Texas-based Dimensional Fund Advsrs Ltd Partnership has invested 0% in Versartis Inc (NASDAQ:VSAR). Northern Trust accumulated 304,935 shares or 0% of the stock. Oxford Asset holds 0.04% or 80,989 shares in its portfolio. State Street has 0% invested in the company for 355,893 shares. Blackrock Invest Mngmt Ltd Limited Liability Company holds 113,158 shares or 0% of its portfolio. Fmr Limited Company holds 3.61 million shares or 0.01% of its portfolio. Natl Bank Of America De reported 3,284 shares or 0% of all its holdings. Swiss National Bank & Trust, a Switzerland-based fund reported 35,400 shares. Wells Fargo & Mn accumulated 0% or 5,540 shares. Legal General Group Public Limited Company accumulated 4,502 shares or 0% of the stock. Jpmorgan Chase And holds 0% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 856,524 shares. Arrowpoint Asset Management Ltd Llc has invested 0.05% of its portfolio in Versartis Inc (NASDAQ:VSAR). Jacobs Levy Equity Management Incorporated holds 0.02% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 102,888 shares. Blackrock Advsr Ltd Co holds 0% or 11,631 shares in its portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock.

Insider Transactions: Since April 21, 2016, the stock had 1 buying transaction, and 6 sales for $6.86 million net activity. $15,392 worth of Versartis Inc (NASDAQ:VSAR) was sold by Brumm Joshua T. 5,442 Versartis Inc (NASDAQ:VSAR) shares with value of $70,093 were sold by Shepard Jay. 725 Versartis Inc (NASDAQ:VSAR) shares with value of $7,707 were sold by Westberg Paul. On Thursday, August 25 Varian John sold $20,755 worth of the stock or 1,600 shares. AKKARAJU SRINIVAS bought $7.00M worth of stock or 571,429 shares.

More news for Versartis Inc (NASDAQ:VSAR) were recently published by:, which released: “Versartis Inc. VSAR (US: Nasdaq)” on March 21, 2014.‘s article titled: “/quotes/zigman/3870025/realtime” and published on March 21, 2014 is yet another important article.

VSAR Company Profile

Versartis, Inc., incorporated on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Firm is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment